Potassium Chloride Extended-Release Capsules Recalled for Failed Dissolution Specifications
Glenmark Pharmaceuticals is recalling potassium chloride extended-release capsules (750 mg) nationwide due to failed dissolution specifications. Affected patients should contact their healthcare provider before making any changes to their medication.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class I recall, which mandates a minimum severity score of 4 per the rubric. No illnesses or injuries have been reported, but the failed dissolution specifications for a prescription extended-release drug represent a risk of inconsistent drug delivery.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling potassium chloride extended-release capsules, USP (750 mg / 10 mEq K) in 100-count bottles (NDC 68462-357-01) due to failed dissolution specifications. Approximately 285,840 bottles distributed nationwide are affected.
Dissolution specifications are critical for extended-release medications to ensure proper drug delivery. Failure to meet these specifications means the medication may not release at the intended rate, potentially affecting the consistency and effectiveness of therapy.
The affected lots include: 17221446, 17221445, 17221393, 17221403, 17221405, 17221503, 17221508, 17221567, 17221566, 17221719, 17221731, 17221891, 17221892, 17221900, 17221992, 17222022, 17222056, 17222043, 17222068, 17222079, 17222099, 17222103, 17222114, 17222119, 17222188, 17222199, 17222209, 17222200, 17222265, 17222269, 17222527, 17222530, 17222583, 17222586, 17230051, 17230075, and 17230067, with expiration dates ranging from May 31, 2024 through November 30, 2024.
Patients taking this medication should contact their healthcare provider before stopping or changing their potassium chloride regimen. Do not use any unused product from the affected lots.
The recalled product
- Product
- POTASSIUM CHLORIDE (POTASSIUM CHLORIDE)
- Brand
- POTASSIUM CHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Hazard
- failed-dissolution
- dosing-variability
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot#: 17221446
- 17221445
- Exp May-31-24
- 17221393
- 17221403
- 17221405
- 17221503
- 17221508
- Exp Jun-30-24
- 17221567
- 17221566
- 17221719
- 17221731
- Exp Jul-31-24
- 17221891
- 17221892
- 17221900
- 17221992
- 17222022
- Exp Aug-31-24
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · POTASSIUM CHLORIDE
- SeverePotassium Chloride Injection Recalled Nationwide for Mislabeled Strength
FDA (Drugs) · 2025-11-26
- CriticalPotassium Chloride Injection Recalled for Incorrect Strength on Overwrap Label
FDA (Drugs) · 2025-11-26
- SeverePotassium Chloride Injection Strength Mislabeled on Packaging Overwrap
FDA (Drugs) · 2025-03-19
- SeverePotassium Chloride Injection Recalled: Overwrap Labeling Shows Incorrect Strength
FDA (Drugs) · 2025-03-19
- HighPotassium Chloride Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2025-02-12
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27